GE Healthcare Introduces New Chromatography Solution for Large Scale Biopharmaceutical Separations
GE Healthcare, a combination of the former Amersham and GE Medical Systems, has launched a second generation STREAMLINE™ family of chromatography solutions, STREAMLINE Direct, designed to improve the ease and economy of protein capture and scale up of biopharmaceutical separation processes. With STREAMLINE Direct, manufacturers of monoclonal antibodies and recombinant proteins can load crude feedstock directly on to columns, with no prior treatment, and benefit from higher flow rates and more robust and reproducible separations.
The solution comprises STREAMLINE Direct columns and a STREAMLINE Direct adsorbent and combines the benefits of the original STREAMLINE expanded bed absorption system with a new design. A high density, adsorbent matrix contains a high-salt tolerant ligand that eliminates the need to dilute the feed stock before loading it onto the column.
The innovative design of STREAMLINE Direct columns eliminates the need for nets, thereby providing trouble-free use of the column at all scales. In addition, STREAMLINE Direct columns allow higher bed heights than the first generation. These new features help to achieve higher product yields, increased reproducibility, free passage of air, and easier cleaning of the column and adsorbent.
STREAMLINE Direct columns and adsorbent offer a robust solution for performing expanded bed adsorption chromatography to capture and purify target proteins directly from the fermentation process – a solution that increases yield and decreases process time.
“STREAMLINE Direct extends our portfolio of upstream processing solutions,” said Günter Jagschies, vice president protein separations marketing at GE Healthcare. “Biopharmaceutical manufacturers will appreciate the improved process economy offered by STREAMLINE Direct.”
GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare’s expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer’s and cardiovascular diseases.
GE Healthcare is a $14 billion unit of General Electric Company (NYSE: GE) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com
